This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Quest Diagnostics (DGX) to Boost Lab Services With New Buyout
by Zacks Equity Research
Quest Diagnostics' (DGX) recent acquisition seeks to increase accessibility to cutting-edge, high-caliber and reasonably priced laboratory services.
Here's Why You Should Retain Omnicell (OMCL) Stock Now
by Zacks Equity Research
Investors are optimistic about Omnicell (OMCL) owing to its strong Pharmacy model and geographical expansion.
Here's Why You Should Retain National Vision (EYE) Stock Now
by Zacks Equity Research
Investors are optimistic about National Vision's (EYE) stock, banking on strong solvency and promising future strategies.
Tandem Diabetes (TNDM) and Abbott Debut New Integrated Offering
by Zacks Equity Research
Tandem Diabetes' (TNDM) t:slim X2 is the first AID system to be integrated with Abbott's Freestyle Libre 2 Plus sensor.
Chemed (CHE) Roto-Rooter Growth Continues, Macro Issues Hurt
by Zacks Equity Research
Within the Hospice segment, Chemed (CHE) is well poised to register growth driven by the growing aging population.
Asensus Surgical (ASXC) Completes Surgeon Lab for LUNA
by Zacks Equity Research
Asensus Surgical's (ASXC) latest Surgeon Lab helps it move closer to a finalized LUNA product.
4 Medical Product Stocks to Buy Amid Industry Challenges
by Indrajit Bandyopadhyay
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. PHG, NEOG, HAE and PBH are well-poised to gain from the favorable factors.
Boston Scientific (BSX) Rides on Global Growth Amid Macro Woes
by Zacks Equity Research
Within APAC, Boston Scientific (BSX) is registering strong growth in Japan and China.
Bruker's (BRKR) New Deal Widens Biopharma PAT Product Portfolio
by Zacks Equity Research
Bruker (BRKR) announces the acquisition of Tornado Spectral Systems Inc., a global provider of chemical analysis & measurement systems for Raman spectroscopy.
Alcon (ALC) Business Hurt by Macroeconomic Woes, Competition
by Zacks Equity Research
In the surgical business, Alcon (ALC) faces a mix of competitors, ranging from large manufacturers with multiple business lines to small manufacturers.
Bruker (BRKR) Expands Materials Science Research via New Deal
by Zacks Equity Research
Bruker (BRKR) announces the acquisition of the electron microscopy company Nion.
Here's Why Investors Should Retain STERIS (STE) Stock for Now
by Zacks Equity Research
Investors continue to remain optimistic about STERIS (STE) due to the prospects of the healthcare business.
Agios Pharmaceuticals (AGIO) Soars 5.2%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Haemonetics (HAE) Up 11% in a Year: Will the Rally Continue?
by Zacks Equity Research
Investors are optimistic about Haemonetics (HAE) owing to its strategic focus on establishing leading positions in high-growth markets and raised guidance.
HAE or SYK: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HAE vs. SYK: Which Stock Is the Better Value Option?
Thermo Fisher (TMO) End Markets Drive Growth Amid Macro Woes
by Zacks Equity Research
In the academic and government end markets, Thermo Fisher (TMO) is delivering strong growth in the electron microscopy, chromatography and mass spectrometry businesses.
Here's Why You Should Retain Edward Lifesciences (EW) Stock Now
by Zacks Equity Research
Investors remain optimistic about Edward Lifesciences (EW) due to the strength of its product group.
Here's Why You Should Retain Medtronic (MDT) Stock for Now
by Zacks Equity Research
Investors are optimistic about Medtronic's (MDT) expansion in global markets and stable solvency position.
Omnicell (OMCL) Gains From Innovation Amid Cost Pressure
by Zacks Equity Research
Omnicell (OMCL) plans to focus on integrating customer success functions into its broader organizational structure.
Here's Why You Should Retain Teleflex (TFX) Stock for Now
by Zacks Equity Research
Investors remain optimistic about Teleflex (TFX), backed by the strong prospects of the Interventional business and stable solvency.
Boston Scientific (BSX) Initiates AVANT GUARD Clinical Trial
by Zacks Equity Research
Boston Scientific's (BSX) AVANT GUARD clinical trial is set to evaluate the FARAPULSE PFA System as the first-line treatment for persistent AF.
Here's Why Haemonetics (HAE) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Globus Medical (GMED) Gains From Innovation Amid Macro Issues
by Zacks Equity Research
Globus Medical (GMED) is particularly seeing notable gains in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.
Here's Why Investors Should Retain Labcorp (LH) Stock for Now
by Zacks Equity Research
Investors remain optimistic about Labcorp (LH) due to impressive partnerships and expansion efforts in targeted high-growth areas.
5 Impressive MedTech Industry Growth Stocks to Buy for 2024
by Moumi Mondal
Stocks such as HAE, PEN, EXAS, PODD and CAH are set to garner remarkable growth for investors.